Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Meloxicam-induced liver toxicity.

P Staerkel1, Y Horsmans

  • 1Department of Gastroenterology, Cliniques Universitaires Saint Luc, Catholic University of Louvain, Brussels, Belgium.

Acta Gastro-Enterologica Belgica
|July 31, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hypogammaglobulinemia, a new risk factor for hepatitis B virus reactivation : about two cases.

Acta gastro-enterologica Belgica·2023
Same author

Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents.

Acta gastro-enterologica Belgica·2021
Same author

Hepatitis C virus (HCV) prevalence estimation in the adult general population in Belgium : a meta-analysis.

Acta gastro-enterologica Belgica·2020
Same author

Impact of liver inflammation on whole body insulin resistance : a case report on primary biliary cholangitis.

Acta gastro-enterologica Belgica·2020
Same author

Results of a screening campaign for hepatitis C viral infection in a Brussels hospital : do we need to go further?

Acta gastro-enterologica Belgica·2019
Same author

Immunisation after hepatitis B polyvalent vaccination among children in South Kivu Province, Democratic Republic of the Congo.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2019
Same journal

A rare twist in the abdomen: diagnostic and therapeutic approaches to omental infarction - a case report and literature review.

Acta gastro-enterologica Belgica·2026
Same journal

GLP-1 receptor agonist-associated eosinophilic duodenitis presenting as a bowel obstruction : a case report and literature review.

Acta gastro-enterologica Belgica·2026
Same journal

Ampullary Actinomycosis Mimicking Malignancy: A Case Report and Literature Review.

Acta gastro-enterologica Belgica·2026
Same journal

Recurrent gastrointestinal bleeding after Peptide Receptor Radionuclide Therapy for a small intestine neuroendocrine tumor.

Acta gastro-enterologica Belgica·2026
Same journal

A little known cause of ischemic colitis.

Acta gastro-enterologica Belgica·2026
Same journal

Linaclotide for irritable bowel syndrome with constipation: integrating realworld evidence into the therapeutic puzzle.

Acta gastro-enterologica Belgica·2026
See all related articles

Meloxicam, a selective cyclooxygenase 2 inhibitor, can cause acute liver damage in rheumatoid arthritis patients. This case highlights potential meloxicam-induced hepatotoxicity and associated antibody development.

Area of Science:

  • Hepatology
  • Rheumatology
  • Pharmacology

Background:

  • Rheumatoid arthritis (RA) management often involves nonsteroidal anti-inflammatory drugs (NSAIDs).
  • Meloxicam, a newer NSAID, selectively inhibits the inducible cyclooxygenase 2 (COX-2) enzyme.
  • Understanding drug-induced liver injury (DILI) is crucial for patient safety.

Observation:

  • A female RA patient developed acute cytolytic hepatitis.
  • Hepatitis onset was rapid following meloxicam administration.
  • The patient developed antinuclear antibodies (ANAs).

Findings:

  • The observed hepatitis was directly linked to meloxicam use.
  • The rapid onset and ANA development suggest a hypersensitivity reaction.
  • This case represents the first reported instance of meloxicam-induced liver toxicity.

Related Experiment Videos

Implications:

  • Meloxicam carries a risk of causing significant hepatic damage.
  • Healthcare providers should monitor for liver function in patients taking meloxicam.
  • Further investigation into the mechanisms of meloxicam hepatotoxicity is warranted.